We tested the hypothesis that the matricellular protein thrombospondin-1 (TSP1), through binding to and activation of the cell receptor CD47, inhibits basal and thermal-mediated cutaneous blood flow. Background: Abnormal and decreased cutaneous blood flow in response to temperature changes or vasoactive agents is a feature of cardiovascular disease and aging. The reasons for decreased cutaneous blood flow remain incompletely understood. Furthermore, a role for matricellular proteins in the regulation skin blood flow has never been proposed. Methods: C57BL/6 wild type, TSP1-null, and CD47-null 12-and 72-weekold male mice underwent analysis of skin blood flow (SkBF) via laser Doppler in response to thermal stress and vasoactive challenge. Results: Young and aged TSP1-and CD47-null mice displayed enhanced basal and thermal sensitive SkBF changes compared with age-matched wild type controls. Nitric oxide-mediated increases in SkBF were also greater in null mice. TSP1 and CD47 were expressed in skin from young wild type mice, and both were significantly upregulated in aged animals. Tissue 3',5'-cyclic guanosine monophosphate, a potent vasodilator, was greater in skin samples from null mice compared with wild type regardless of age. Finally, treating wild type animals with a CD47 monoclonal antibody that inhibits TSP1 activation of CD47 enhanced SkBF in both young and aged animals. Conclusions: These results suggest that secreted TSP1, via its cognate receptor CD47, acutely modulates SkBF. These data further support therapeutically targeting CD47 to mitigate age-associated loss of SkBF and maximize wound healing.
contributor to the pathogenesis and chronicity of soft tissue wounds, though the reasons for altered SkBF remain incompletely defined. Conversely, the goal of enhancing SkBF to increase wound healing has met with limited experimental and clinical success. 10, 11 The biogas nitric oxide participates in the regulation of SkBF 12, 13 and wound healing. 14, 15 Loss of nitric oxide bioavailability and sensitivity contributes to abnormal SkBF, [16] [17] [18] whereas therapeutic enhancement of nitric oxide signaling increases SkBF in preclinical models. [19] [20] [21] Studies in human subjects also suggest a role of nitric oxide in the regulation of SkBF, 22 with local thermally induced cutaneous vasodilation mediated substantially through nitric oxide signaling. 23 Loss of cutaneous nitric oxide and decreased cutaneous vasodilatory response 24 are associated with decreased healing capacity in the elderly. 25 , 26 Yet it is not known what factors account for the age-associated loss of cutaneous nitric oxide signaling.
The secreted matricellular protein thrombospondin-1 (TSP1) is unregulated in several disease states that are associated with loss of SkBF and impaired wound healing including diabetes, scleroderma, 27 and systemic sclerosis 28 and has recently been postulated to account for the loss of cutaneous blood flow in these individuals. 29 In preclinical models of cutaneous wound healing TSP1 antisense oligomers delayed wound healing 30 and overexpression of TSP1 in the skin of mice greatly slowed wound closure and wound-associated angiogenesis. 31 We have reported that TSP1-and CD47-null mice demonstrated enhanced ischemic wound healing in aged animals compared with wild type controls. 21 Herein then, we tested the hypothesis that temperature-and age-associated changes in SkBF are limited by TSP1-activation of the cell-receptor CD47. TSP1-and CD47-null mice displayed enhanced basal cutaneous blood flow and a greater dynamic response in flow to both core temperature changes and pharmacologic activation of the nitric oxide pathway than wild type controls at any age. These findings were associated with enhanced levels of the nitric oxide second messenger 3',5'-cyclic guanosine monophosphate in skin from null mice regardless of age. In wild type murine skin, TSP1 and CD47 expression increased with age and were paralleled by a concurrent drop in nitric oxide signaling and SkBF. Finally, blocking CD47 activation in wild type mice with an antibody that prevents TSP1 binding to CD47 increased cutaneous flow in young and aged mice. Together these data suggest (1) that induction of the TSP1-CD47 signaling axis may account, in part, for age-associated decreases in cutaneous nitric oxide signaling and SkBF, and (2) that CD47 targeting enhances skin blood flow and may promote wound healing.
MATERIALS AND METHODS Animals
C57BL/6 male wild type, TSP1-null, and CD47-null mice (Jackson Lab stock numbers 000664, 006141, and 003173, respectively) were maintained in a pathogen-free environment with ad libitum access to standard rat chow and water. Animal ages at the time of use were 12 or 72 weeks as indicated. Care and handling of animals was in accordance with the Institutional Animal Care and Use Committees of the National Institutes of Health and of the University of Pittsburgh School of Medicine. Hair from the dorsum of the animals was removed with electric shears followed by a depilatory lotion (Nair) before laser Doppler flow measurements.
Laser Doppler Analysis of Skin Blood Flow
Core temperature was monitored via rectal probe and maintained at 37.5
• C by a heating pad and warming lamp. In experiments where core temperature was altered, the heating lamp and pad were adjusted to raise or lower core temperature by 0.5
• C intervals. Animals were acclimated at new core temperatures for 15 minutes before laser Doppler analysis. Anesthesia was obtained with isoflurane (1.5% wild type and TSP1-null mice; 1.2% CD47 null mice) with a 50:50 ratio of oxygen to room air via nose cone inhalation. (See later for an explanation concerning the variation in anesthesia dosing between mouse strains.) A MoorLDλ 1-2 laser Doppler scanner (Moor Instruments, Devon, England) was used to acquire real time cutaneous blood flow data with the following parameters: scan area, 1.6 × 2.5 cm; scan speed, 4 ms per pixel; scan time, 1 minute 54 seconds; and override distance, 25 cm.
Blood Pressure Measurement
We have published that CD47-null mice display decreased mean arterial blood pressure at rest compared with wild type and TSP1-null animals. 32 For this reason, we placed femoral arterial catheters (Millar Mikro-Tip pressure Catheter) in age-matched wild type, TSP1-null, and CD47-null mice and monitored mean arterial blood pressure under inhalation of isoflurane anesthesia. Though mean arterial blood pressure at a concentration of 1.5% isoflurane trended slightly lower in CD47-null mice, decreasing the concentration of anesthetic to 1.2% brought mean arterial blood pressure in CD47-null animals to within 3 to 5 mm Hg of values recorded in wild type and TSP1-null animals.
Vasoactive Challenge Experiments
Baseline SkBF data were obtained in animals (n = 6 per strain/treatment group). Animals then received a vasoactive challenge with the primary nitric oxide donor (DEA-NO, 100 nmol/g body weight in 100 μL prewarmed normal saline via rectal instillation) or the endothelial nitric oxide synthase activator acetylcholine (acetylcholine, 0.08 μg/g weight in 100 μL prewarmed normal saline via intraperitoneal injection) and 60 seconds later cutaneous blood flow was measured via laser Doppler.
Therapeutic Blockade of TSP1-CD47 Signaling
Age-matched male C57BL/6 wild type mice were randomized into 1 of 4 groups: no treatment, vehicle (sterile phosphate-buffered saline), CD47-blocking antibody (clone 301), or isotype-matched control antibody. Treatments were administered via intraperitoneal injection. Blood flow analysis was performed via laser Doppler 3 hours later. Antibody dose (0.4 μg/g weight intraperitoneal in 100 μL sterile phosphate-buffered saline) was based on our prior published data showing therapeutic efficacy.
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Protein Expression by Western Blot
Sections of dorsal skin were homogenized in ice-cold lysis buffer containing NP-40, protease inhibitor cocktail (Sigma), sodium fluoride, sodium orthovanadate, and PhosStop (Roche), centrifuged at 12,000 rpm for 20 minutes at 4
• C; supernatants collected and lysates stored at −20
• C. Protein was quantified using a Bradford assay (BioRad). Thirty micrograms of total protein was boiled, resolved by SDS-PAGE and transferred onto nitrocellulose (BioRad). In blots for CD47, nonreducing Laemmli buffer was used with 8% SDS-PAGE as previously published. 34 Blots were probed with primary antibody to the respective proteins and were visualized after 1-hour incubation in secondary antibody on an Odyssey Imaging System (Licor). The following antibodies were employed: mouse anti-thrombospondin-1 (Abcam, 1:500 dilution, Cat. No. ab1823); goat anti-CD47 C-18 (Santa Cruz, 1:500 dilution), and rabbit anti-β-actin (Cell Signaling, dilution 1:5000, Cat. No. 4967). The intensity of the bands was quantified using the Odyssey software or Image J (http://rsbweb.nih. gov/ij/).
Determination of mRNA Transcript
TSP1 and CD47 messenger ribonucleic acid (mRNA) levels in skin samples from 12-and 72-week-old C57BL/6 wild type mice were determined by real-time quantitative polymerase chain reaction. Specific Taqman primers and probes for (Mm_01545399_m1), CD47 (Mm_00495005_m1), and TSP1 (Mm_01335418_m1) were obtained from Applied Biosystems (Carlsbad, CA). Total ribonucleic acid (RNA) was extracted using Qiagen RNeasy Mini Kits (Qiagen, Hilden, Germany) and Proteinase K digestion per the manufacturer instructions. RNA was quantified using the Take3 Gen5 spectrophotometer (BioTek, Winooski, VT). One microgram of RNA was treated with DNase I (amplification grade, Invitrogen, Grand Island, NY) and then reverse-transcribed using the Superscript III First Strand Synthesis Supermix (Invitrogen). Complementary deoxyribonucleic acid was amplified using Platinum Quantitative PCR SuperMix-UDG (Invitrogen) in 20 μL volumes in triplicate with gene-specific primers and probe on the ABI Prism 7900HT Sequence Detection System (Applied Biosystems), according to manufacturer instructions. Thermal cycling conditions were 50
• C for 2 minutes, 95
• C for 2 minutes, followed by 40 cycles of 95
• C for 15 seconds and 60
• C for 1 minute. Data were analyzed using the Ct method with expression normalized to the housekeeping gene.
Determination of Tissue Cyclic Guanosine Monophosphate
Skin cyclic guanosine monophosphate was measured as we have published previously 35 with slight modification. Briefly, skin biopsies of equal wet weight were excised, flash frozen in liquid nitrogen and pulverized in a mortar and pestle. Homogenates of the pulverized tissue were prepared, lysis buffer chilled to 4
• C, centrifuged at 4
• C and supernatants were used for analysis via immunoassay (Amersham, GE Healthcare) per the manufacture instructions.
Statistics
Significance was calculated with the Student t test and 1-way or 2-way analysis of variance as appropriate, with a Bonferroni posttest using a software package (GraphPad Prism 5, La Jolla, CA) with P < 0.05 taken as significant.
RESULTS
Cutaneous TSP1 and CD47 Expression Increases With Age
In the absence of injury or disease, TSP1 expression is minimal. 29, 36 However, with acute injury, TSP1 expression increases rapidly. 37 In preclinical models, age-associated induction of TSP1 has been described in the kidney 38 and heart. 39 To date, little is know about CD47 expression in health or disease. Analysis of cutaneous biopsies from wild type male mice at 12 weeks demonstrated expression of both TSP1 and CD47 protein and mRNA (Figs. 1A-C) . In cutaneous samples from age 72-week-old mice, both TSP1 and CD47 protein and CD47 transcript increased significantly (Figs. 1A-C). Interestingly though, in aged skin TSP1 mRNA was significantly decreased. These data provide the first evidence of age-associated induction of tissue CD47.
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. FIGURE 1. Cutaneous TSP1 and CD47 protein and messenger ribonucleic acid (mRNA) are increased with age. Biopsies of skin from the dorsum of 12-and 72-week-old male C57BL/6 mice were collected, tissue lysates prepared, protein separated by SDS-PAGE and Western blotted for TSP1 and CD47. A, Densitometry represents the mean ± standard deviation of blots prepared from distinct tissue samples from individual mice (n = 4, 12-week-old mice, and n = 5, 72-week-old mice).
* indicates P < 0.05 compared with 12-week-old animals. B, real-time quantitative polymerase chain reaction analysis of TSP1 and CD47 mRNA. C, Results normalized to hypoxanthine phosphoribosyltransferase 1 are the mean ± standard deviation of material prepared from animal cohorts described in A.
* indicates P < 0.05 compared to 12-week-old animals.
TSP1 and CD47 Limit Basal Cutaneous Blood Flow
We have published that TSP1 and CD47 are hypertensive and support blood pressure. 32, 40 To control this in the present work, we measured blood pressure in age-matched wild type, TSP1-null, and CD47-null mice and adjusted the concentration of inhalation anesthesia accordingly to achieve parity in mean arterial blood pressure between strains (see the Methods section). We now show in 12-weekold mice, at a constant core temperature of 37.5
• C, that SkBF is significantly greater in both TSP1-and CD47-null mice than in wild type C57BL/6 controls ( Fig. 2A) . These findings are important in light of our recent report that physiologically relevant TSP1 signaling occurs through binding to and activation of cell receptor CD47. 
Temperature-Induced Changes in Blood Flow Are Limited by TSP1 and CD47
Thermal stress alters SkBF, and this process is both directly and indirectly mediated via nitric oxide. 42, 43 We reported that blood vessels from TSP1-and CD47-null mice demonstrate enhanced vasodilatation in ex vivo myography bioassays compared with wild type controls. 40 Considering these findings, we tested the hypothesis that SkBF changes to thermal stress are limited by TSP1 and CD47. Beginning with animals at a core temperature of 34
• C, we increased core body temperature by 0.5 • C to a maximum of 38 • C and measured cutaneous blood flow after each thermal adjustment. Interestingly, both TSP1-and CD47-null mice showed increased SkBF under basal conditions that persisted throughout the period of controlled elevation of the core body temperature as compared with wild type (Fig.  2B) . Likewise, TSP1-and CD47-null mice also showed maintenance of greater cutaneous perfusion during periods of controlled cooling (Fig. 2C) . Null mice did experience a drop in SkBF with cooling, however, at the lowest core temperature achieved, TSP1-and CD47-null mice still demonstrated approximately 25% greater SkBF than wild type animals, suggesting a possible primary deficiency in the reflex protection of core temperature in null animals.
Vasoactive Alterations in SkBF Are Regulated by TSP1 and CD47
We treated mice with the primary nitric oxide-donor diethylamine NONOate (DEA-NO, t 1 / 2 = 30 seconds) to assess endothelialindependent effects on SkBF, and acetylcholine (a physiological activator of endothelial nitric oxide synthase that has been reported to alter SkBF 44 ) to test endothelial-dependent blood flow effects. Consistent with enhanced basal cutaneous blood flow, SkBF in TSP1-and CD47-null animals was greater after treatment with DEA-NO FIGURE 2. Basal and thermal-mediated SkBF is increased in the absence of TSP1 and CD47. Under general anesthesia, 12-week-old male wild type, TSP1-null, and CD47-null mice underwent SkBF analysis with core temperature maintained at 37
• C. A, Typical images of real time laser Doppler analysis are presented for wild type, TSP1-null, and CD47-null mice. Results represent the mean ± standard deviation of 6 animals of each strain.
* and † indicate P < 0.05 compared with wild type. Under general anesthesia, 12-week-old male C57BL/6 wild type, TSP1-null, and CD47-null mice under went SkBF analysis with laser Doppler beginning at 37
• C, followed by controlled elevation of core temperature by 0.5
• C with SkBF determined at each new core temperature, proceeding to a maximum core temperature of 38
• C. B, Typical images of real time laser Doppler analysis are presented for wild type, TSP1-null, and CD47-null mice at the indicated core temperatures. Results represent the mean ± standard deviation of 6 mice of each strain. * indicates P < 0.05 compared to wild type. Under general anesthesia, 12-week-old male C57BL/6 wild type, TSP1-null, and CD47-null mice underwent SkBF analysis with laser Doppler beginning at 38
• C, followed by controlled lowering of core temperature by 0.5
• C with SkBF determined at each new core temperature, proceeding to a core temperature of 32
• C. C, Results represent the mean ± standard deviation of 6 mice of each strain. * indicates P < 0.05 compared to wild type.
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( Fig. 3A) and also greater after treatment with acetylcholine in TSP1-null animals (Fig. 3B ) compared with controls. To further assess the role of nitric oxide in the aforementioned results, we treated mice with the endothelial nitric oxide synthase-inhibitor L-nitro-L-arginine methyl ester. Basal wild type and TSP1-and CD47-null SkBF normalized after L-nitro-L-arginine methyl ester treatment (data not shown).
Age-Associated Alterations in SkBF Are Less Prominent in TSP1-and CD47-Null Mice
Loss of cutaneous blood flow, associated tissue necrosis, and poor wound healing are known consequences of age and certain vasculopathies. 27, 28, 45 We have reported that skeletal muscle blood flow is maintained in old TSP1-and CD47-null mice compared with old wild type animals. 21 These findings suggested that TSP1-CD47 signaling may also limit SkBF in aged animals. We tested this hypothesis in 72-week-old wild type and null mice. Both basal and thermal associated changes in SkBF were greater in 72-week-old TSP1-and FIGURE 3. Nitric oxide-mediated effects on SkBF are limited by TSP1 and CD47. Under general anesthesia, 12-week-old male C57BL/6 wild type, TSP1-null, and CD47-null mice underwent SkBF analysis with laser Doppler with core temperature maintained constant at 37
• C. After a 30 minute stabilization interval basal SkBF was determined, and animals were challenged with either vehicle (normal saline) or the primary nitric oxide donor DEA-NO (100 nmol/g body weight via rectal instillation) (A), or the endothelial nitric oxide synthase activator acetylcholine (0.08 μg/gram weight via intravenous injection; wild type and TSP1-null mice) (B) and SkBF determined. Results are the mean ± standard deviation of 6 animals of each strain.
* and † indicate P < 0.05 compared to wild type.
CD47-null mice than in wild type controls, though statistical significance was only obtained in CD47-null mice (Fig. 4A) .
Tissue Cyclic Guanosine Monophosphate Is Elevated in Young and Old TSP1-and CD47-Null Skin Samples
Nitric oxide activation of soluble guanylyl cyclase results in rapid production of cyclic guanosine monophosphate and subsequent FIGURE 4. Aged TSP1-and CD47-null mice maintain SkBF and nitric oxide signaling. Under general anesthesia, 72-week-old male wild type, TSP1-null, and CD47-null mice with core temperature maintained at 37
• C underwent SkBF determination via laser Doppler. Results are the mean ± standard deviation of 6 animals of each strain. * indicates P < 0.05 compared with wild type. Dorsal cutaneous skin samples from 12-week (B) or 72-week (C) old male wild type, TSP1-null, and CD47-null mice were harvested, snap frozen in liquid nitrogen, pulverized, homogenized in lysis buffer, and assayed for tissue cyclic guanosine monophosphate as via ELISA (Amersham, GE Healthcare).
vasodilation.
46,47 Analysis of tissue cyclic guanosine monophosphate levels in freshly harvested skin biopsies demonstrated increased cyclic guanosine monophosphate in samples from 12-week-old TSP1-and CD47-null mice compared with wild type mice (Fig. 4B) . Surprisingly, analysis of cyclic guanosine monophosphate levels in skin from 72-week-old TSP1-and CD47-null mice confirmed persistent elevation of cutaneous cyclic guanosine monophosphate (Fig. 4C) . In contrast, cutaneous cyclic guanosine monophosphate levels decreased with age in wild type mice (Fig. 4C ). These findings demonstrate persistence of nitric oxide signaling in null animals independent of the aging process and suggest that age-associated loss of nitric oxide signaling may be secondary, in part, to induction of the activated CD47 axis.
Interruption of CD47 Activation Enhances SkBF
Loss of adequate skin blood flow contributes to delayed healing and wound chronicity in the elderly. 8, 48, 49 We have identified several therapeutic agents that effectively block the TSP1-CD47 signaling axis through preventing TSP1 binding to and activation of CD47. 33, 35, 50 We tested the potential for one of these therapeutic agents, by blocking TSP1-CD47 signaling, to enhance SkBF. A CD47 monoclonal antibody (clone 301) was given to 12-week-old wild type mice before laser Doppler assessment of SkBF. Interestingly, wild type animals demonstrated enhanced SkBF under basal conditions (Fig. 5A ) compared with animals treated with an isotype IgG2α control antibody. Importantly, treating 72-week-old wild type mice with the CD47-blocking antibody also increased SkBF (Fig. 5B) .
DISCUSSION
To our knowledge, this is the first report to demonstrate in preclinical studies that matricellular TSP1 is an immediate regulator of cutaneous blood flow via its activation of CD47 signaling. SkBF was greater under basal conditions in TSP1-and CD47-null animals and in response to both vasoactive and thermal challenges, suggesting a global upregulation in flow in the absence of activated CD47. Aged null animals lacking activated CD47 demonstrated more robust SkBF than wild type controls and minimal changes in SkBF compared with young CD47 null animals, suggesting a primary role for activated CD47 in age-associated deficiencies in SkBF.
Autonomic pathways are known to control SkBF, and we have reported that TSP1-null mice display greater shifts in blood flow after postganglionic autonomic blockade with hexamethonium chloride. 32 It is possible that differences in autonomic signaling play a role in SkBF flux measured in null mice.
The acute effects of TSP1 on SkBF identified here are distinct from its previously reported chronic effects on tissue perfusion via its antiangiogenic activity. Cutaneous TSP1 limits ultraviolet lightmediated angiogenesis in part through limiting vascular endothelial growth factor (VEGF) signaling to decrease cutaneous vascularity. 51 We have shown that activated CD47 inhibits both nitric oxide-and VEGF-driven angiogenesis in endothelial cells. 34, 52 Also antibody blockade of TSP1 35 or gene suppression of CD47 53 can increase cutaneous vascularity and subsequent blood flow. However, we have reported comparable vascular density under basal conditions in skin in 12-week-old wild type and null mice, though in wound and ischemic models TSP1-and CD47-null cutaneous tissue units show enhanced vascularity at 3-and 7-day intervals. 53, 54 Nonetheless, young TSP1-and CD47-null mice have more basal cutaneous blood flow and show persistence of this advantage in SkBF after core temperature changes or nitric oxide pathway activation supporting a role for activated CD47 in the acute regulation of SkBF. However, it is not clear why SkBF is not more responsive to changes in core temperature alterations in TSP1-and CD47-null mice. Particularly unexpected was our finding that at a core temperature of 32
• C TSP1-and CD47-null mice still maintained significantly increased SkBF compared with wild type mice. Such a result predicts a difficulty in null mice in maintaining core temperature in response to environmental challenge. Though this work cannot address this, these data are consistent with previous findings by our group of limited homeostasis in TSP1-and CD47-null mice to several stresses including anesthetic agents, vasodilators and sympathetic tone blockade. 32 Interestingly, cutaneous TSP1 and CD47 levels increase with age. It is not clear whether age-associated induction represents altered production, degradation, or stability of these proteins. Given the identified role of TSP1 in inhibiting angiogenesis, the decreased SkBF in older wild type mice may in part be secondary to decreased cutaneous vascular density. However, our data reveal that in aged animals activated CD47 also limits SkBF through an acute regulatory mechanism. Findings of increased expression of ligand TSP1 and cell receptor CD47 in aged skin are in agreement with our recent report of concurrent upregulation of both TSP1 and CD47 protein and mRNA in human and preclinical models of pulmonary arterial hypertension, 55 suggesting linked gene regulation of these proteins. Blockade of CD47 activation with a monoclonal antibody recapitulated null levels of cutaneous SkBF in wild type animals. This therapeutic advantage was enjoyed by antibody-treated young and aged wild type mice. Increased cutaneous blood flow was detected shortly after a single injection of antibody. Hence, the enhanced SkBF experienced by treated wild type animals represents an acute response FIGURE 5. Therapeutic blockade of CD47 activation increases SkBF; 12-week (A) or 72-week (B) old male wild type C57BL/6 mice were treated with a CD47 blocking antibody (clone 301, 40 μg delivered as 10 μL of a 4 mg/mL stock in 100 μL of PBS in injected in the skin) or an isotype IgG2α control antibody as we had previously published. 53 Three hours later, animals underwent general anesthesia with their core temperature maintained at 37
• C for 30 minutes before assessment of SkBF via laser Doppler. Results presented are the mean ± standard deviation of 4 animals in each treatment group.
* indicates P < 0.05 compared to isotype control antibody treated and untreated.
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. from existing cutaneous vascular networks rather than induction of angiogenesis. In addition, the activity of CD47 to inhibit both nitric oxide- 56 and VEGF-34 mediated angiogenesis predicts that therapeutic targeting of CD47 will result in beneficial effects at the level of acute increases in blood flow and through increased angiogenesis. Thus, these data predict that drugs targeting CD47 will be in many ways beneficial in enhancing blood flow and wound healing in the elderly.
